BR9909672A - uso de um composto medicinal ativo no preparo de um medicamento para o tratamento de hipertensão - Google Patents

uso de um composto medicinal ativo no preparo de um medicamento para o tratamento de hipertensão

Info

Publication number
BR9909672A
BR9909672A BRPI9909672-2A BR9909672A BR9909672A BR 9909672 A BR9909672 A BR 9909672A BR 9909672 A BR9909672 A BR 9909672A BR 9909672 A BR9909672 A BR 9909672A
Authority
BR
Brazil
Prior art keywords
hypertension
nsaid
vitamin
supplement
medicament
Prior art date
Application number
BRPI9909672-2A
Other languages
English (en)
Inventor
Krishnamurti Dakashinamurti
Rajat Sethi
Naranjan S Dhalla
Original Assignee
Univ Manitoba
Medicure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba, Medicure Inc filed Critical Univ Manitoba
Publication of BR9909672A publication Critical patent/BR9909672A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

USO DE UM COMPOSTO MEDICINAL ATIVO NO PREPARO DE UM MEDICAMENTO PARA O TRATAMENTO DE HIPERTENSãO. A hipertensão em pacientes mamíferos, especialmente pacientes humanos idosos, causada por ingestão de NSAIDs ou pelo processo normal de envelhecimento Þ tratada pela administração ao paciente de um suplemento de vitamina B6 (ou derivados). Quando o pciente requer a administração contínua de um NSAID com finalidades farmacológicas, o NSAID é administração em conjunto com um suplemento de vitamina B6. A invenção proporciona também combinações farmacêuticas de um NSAID e um suplemento de vitamina B6, por exemplo comprimidos ou cápsulas para dministração por via oral, para uso no tratamento de tais estados.
BRPI9909672-2A 1998-04-16 1999-04-16 uso de um composto medicinal ativo no preparo de um medicamento para o tratamento de hipertensão BR9909672A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/061,173 US6051587A (en) 1998-04-16 1998-04-16 Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
PCT/CA1999/000331 WO1999053928A1 (en) 1998-04-16 1999-04-16 Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein

Publications (1)

Publication Number Publication Date
BR9909672A true BR9909672A (pt) 2007-07-31

Family

ID=22034118

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9909672-2A BR9909672A (pt) 1998-04-16 1999-04-16 uso de um composto medicinal ativo no preparo de um medicamento para o tratamento de hipertensão

Country Status (12)

Country Link
US (1) US6051587A (pt)
EP (1) EP1071430B1 (pt)
JP (1) JP2002512194A (pt)
AT (1) ATE319457T1 (pt)
AU (1) AU765749B2 (pt)
BR (1) BR9909672A (pt)
CA (1) CA2328730C (pt)
DE (1) DE69930243T2 (pt)
ES (1) ES2260906T3 (pt)
IL (1) IL139681A0 (pt)
NZ (1) NZ508142A (pt)
WO (1) WO1999053928A1 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
JP2002539127A (ja) 1999-03-08 2002-11-19 メディキュア インコーポレーテッド ビタミンｂ−６障害のためのピリドキサル類縁体
US6489345B1 (en) * 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
WO2001013900A2 (en) * 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
EP1531157B1 (en) * 2000-02-29 2008-03-19 Medicure International Inc. Cardioprotective phosphonates
WO2001064692A1 (en) 2000-02-29 2001-09-07 Medicure International Inc. Cardioprotective phosphonates and malonates
US7442689B2 (en) 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
AU784840B2 (en) 2000-03-28 2006-07-06 Medicure International Inc. Treatment of cerebrovascular disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
MXPA05001202A (es) 2002-07-29 2005-11-23 Hawaii Biotech Inc Analogos carotenoides estructurales para la inhibicion y mejora de la enfermedad.
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2004084910A1 (en) * 2003-03-27 2004-10-07 Medicure Inc. Compositions for treating angina
WO2004084895A2 (en) * 2003-03-27 2004-10-07 Medicure, Inc. Modulation of cell death
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005102356A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
CN101035543A (zh) * 2004-08-10 2007-09-12 麦迪库瑞国际公司 维生素b6相关化合物与ace抑制剂的联合疗法及其治疗糖尿病病症的用途
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
CA2585165A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
WO2006056078A1 (en) * 2004-11-26 2006-06-01 Medicure International Inc. Novel formulation of pyridoxal 5'-phosphate and method of preparation
WO2006072172A1 (en) * 2005-01-05 2006-07-13 Medicure International Inc. Compounds and methods for regulating triglyceride levels
US20060270590A1 (en) 2005-03-29 2006-11-30 Lockwood Samuel F Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
CA2503087A1 (en) * 2005-03-30 2006-09-30 Medicure International Inc. Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
JP2009517411A (ja) * 2005-11-28 2009-04-30 メディキュア インターナショナル インコーポレーテッド 心血管及び関連病状の処置のための調剤
DOP2007000055A (es) 2006-04-10 2007-10-31 Senosiain S A De C V Lab Composición farmaceutica que comprende un analgésico y vitaminas
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
MX2008003230A (es) * 2008-03-07 2009-09-07 Senosiain S A De C V Lab Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b.
ITMI20121316A1 (it) * 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
EP2908858B1 (en) * 2012-10-19 2020-06-24 New York University Compositions for use in inhibiting osteolysis
RU2629367C1 (ru) * 2016-11-02 2017-08-29 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Нестероидное противовоспалительное средство на основе напроксена, обладающее низкой гастротоксичностью

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4492M (pt) * 1965-07-07 1966-10-10
FR6707M (pt) * 1966-04-29 1969-02-17
FR6723M (pt) * 1966-12-30 1969-02-17
FR7503M (pt) * 1967-05-30 1969-12-08
GB1236531A (en) * 1969-02-12 1971-06-23 Soc D Etudes Prod Chimique Adenin derivative
JPS53121765A (en) * 1977-04-01 1978-10-24 Chugai Pharmaceut Co Ltd Pyridoxal derivatives
IL62602A (en) * 1980-05-19 1984-06-29 Labaz Sanofi Nv Pyridoxine derivatives,their preparation and pharmaceutical compositions containing them
US4542026A (en) * 1983-04-29 1985-09-17 Jose Rios Method of treating vasomotor disorders
US4564614A (en) * 1984-10-11 1986-01-14 Pfizer Inc. Antiinflammatory methods
FR2641189B1 (fr) * 1988-06-20 1991-05-10 Timol Mamoojee Compositions pharmaceutiques contenant de l'acide acetyl salicylique et de la vitamine b6
US20040180865A1 (en) * 1993-06-04 2004-09-16 Jeffry W. Kreamer Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease

Also Published As

Publication number Publication date
DE69930243D1 (de) 2006-05-04
WO1999053928A1 (en) 1999-10-28
NZ508142A (en) 2002-11-26
IL139681A0 (en) 2002-02-10
AU765749B2 (en) 2003-09-25
US6051587A (en) 2000-04-18
EP1071430A1 (en) 2001-01-31
JP2002512194A (ja) 2002-04-23
AU3402999A (en) 1999-11-08
ATE319457T1 (de) 2006-03-15
EP1071430B1 (en) 2006-03-08
CA2328730C (en) 2007-08-21
ES2260906T3 (es) 2006-11-01
DE69930243T2 (de) 2006-12-07
CA2328730A1 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
DE69930243D1 (de) Behandlung iatrogenen und altersbedingten bluthochdruck mit vitamin b6-derivative, und pharmazeutische zusammensetzungen verwendbar dazu
US6841544B2 (en) Composition and method for treating the effects of diseases and maladies
US6787164B2 (en) Composition and method for treating the effects of diseases and maladies
US6576267B2 (en) Composition and method for treating the effects of diseases and maladies
NO964864D0 (no) Orale, flytende alendronatpreparater
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer&#39;s disease
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
JP4411414B2 (ja) 糖尿病性神経障害の治療に対する組成物及びその方法
KR970061244A (ko) 치매 치료용 약학 조성물
RU2000114174A (ru) Применение фосфолипидных комплексов экстрактов из vitis vinifera в качестве противоатеросклеротических агентов
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
Passàli et al. Efficacy and safety of ketoprofen lysine salt mouthwash versus benzydamine hydrochloride mouthwash in acute pharyngeal inflammation: a randomized, single-blind study
CA2382887A1 (en) Immunopotentiating compositions
JPH04243825A (ja) 色素沈着症治療剤
KR19990077143A (ko) 디오스게닌을 함유하는 조성물
JPH01261334A (ja) アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法
BRPI0415322A (pt) composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina
US20020034555A1 (en) Composition and method for treating the effects of diseases and maladies
AU2002363874A1 (en) Use of desoxypeganine for treating clinical depression
RU2001119623A (ru) Способ снижения содержания церамидов, набор, включающий антиретровирусное лекарственное средство
BR0208920A (pt) Inibidor de aromatase em dose única para tratamento de infertilidade
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására
JP4706174B2 (ja) α−グルコシダーゼ阻害剤
CA2403674A1 (en) The use of t3 for treating congestive heart failure

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/675 (2008.04), A61K 31/44 (2008.04), A61K

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.